Collegium Pharmaceutical, Inc.
S&P 600
$22.75
-0.74%
Delayed · cached 15 min
Fair value analysis
COLL
Collegium Pharmaceutical, Inc.
$22.75
Close used for this calculation
$10.88Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
49/100
Quality radar
Consensus fair value
$10.88
Above FV▼ -52.2% against the close used
Model range $5.43 – $23.53
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear$5.43Fair value$10.88Bull$23.53
FairClose
52-week traded range
52W low $22.7552W high $49.84
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Collegium Pharmaceutical, Inc. closed at $22.75, 109.1% above the consensus fair value of $10.88 drawn from 7 valuation models.
Financial DNA score 49/100 — Average. P/E of 49.5x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
$8.62
-62.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
P/E Fair Value
$9.20
-59.6%
EPS × 20x (sector P/E)
EPS=0.46, Sector P/E=20x
Peter Lynch (PEG)
$5.43
-76.1%
EPS × Growth% (PEG = 1 is fair)
EPS=0.46, g=11.8%
EV/EBITDA
$13.45
-40.9%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=183.82M
Book Value (P/B)
$23.53
+3.4%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=9.6, ROE=20.2%, g=3%, r=10%
Reverse DCF
$22.75
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 19.4% | Historical: -11.8%
Margin of Safety
$6.68
-70.6%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=8.91, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.